Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 10/20 | 1.00 |
| ▸ | STAT3 | P40763 | 1/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 1/20 | 1.00 |
| ▸ | FLT3 | P36888 | 3/20 | 0.66 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.62 |
| ▸ | NPC1 | O15118 | 4/20 | 0.59 |
| ▸ | CDK2 | P24941 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.59 |
| ▸ | RAB9A | P51151 | 3/20 | 0.58 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.58 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 3/20 | 0.58 |
| ▸ | HTT | P42858 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.57 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.57 |
| ▸ | RELA | Q04206 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29805260 | 1.00 | KDM4E (1.00) | KDM4ESTAT3HIF1AFLT3YTHDC1 | |
| SCHEMBL14268188 | 0.83 | KDM4E (0.71) | KDM4ESTAT3HIF1AFLT3YTHDC1 | |
| SCHEMBL25380488 | 0.83 | KDM4E (0.71) | KDM4ESTAT3HIF1AFLT3YTHDC1 | |
| SCHEMBL11485891 | 0.83 | KDM4E (0.71) | KDM4ESTAT3HIF1AFLT3YTHDC1 | |
| SCHEMBL29709972 | 0.82 | KDM4E (1.00) | KDM4ESTAT3HIF1ASMN1; SMN2NPC1 | |
| SCHEMBL5435670 | 0.82 | KDM4E (0.69) | KDM4ESTAT3HIF1AFLT3YTHDC1 | |
| SCHEMBL959364 | 0.82 | KDM4E (1.00) | KDM4ESTAT3HIF1ASMN1; SMN2NPC1 | |
| SCHEMBL638166 | 0.81 | POLB (0.70) | KDM4ESTAT3HIF1ASMN1; SMN2NPC1 | |
| SCHEMBL21449273 | 0.81 | KDM4E (0.68) | KDM4ESTAT3HIF1AFLT3YTHDC1 | |
| SCHEMBL4464792 | 0.81 | KDM4E (0.68) | KDM4ESTAT3HIF1AFLT3YTHDC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 396 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122080068-A | Mitochondria-targeted lonidamine and cinnamaldehyde coupled prodrug as well as preparation method and application thereof | — | 2026-05-26 | — | — | CN | claimed |
| CN-113929627-A | Synthetic method of bindarit | 吕梁学院 | 2022-01-14 | — | — | CN | claimed |
| CN-110003187-B | Polyfluoroalkyl substituted benzofuran compound and preparation method thereof | 南京工业大学 | 2021-11-05 | — | — | CN | claimed |
| CN-110003187-A | Polyfluoroalkyl substituted benzofuran compound and preparation method thereof | 南京工业大学 | 2019-07-12 | — | — | CN | claimed |
| CN-122079973-A | Fatty nitroamine deamination functionalization process | — | 2026-05-26 | — | — | CN | disclosed |
| CN-122080068-A | Mitochondria-targeted lonidamine and cinnamaldehyde coupled prodrug as well as preparation method and application thereof | — | 2026-05-26 | — | — | CN | disclosed |
| CN-122059947-A | Deamination functionalization method of fatty amine | 国科大杭州高等研究院 | 2026-05-19 | — | — | CN | disclosed |
| CN-117177975-B | Pyrimido [5,4, D ] pyrimidine compounds, compositions comprising the same and uses thereof | 蒙特利尔大学 | 2026-05-19 | — | — | CN | disclosed |
| CN-122036679-A | Preparation method and application of indazole carboxylic acid | 广东大丰植保科技有限公司 | 2026-05-15 | — | — | CN | disclosed |
| CN-122036615-A | Indazole hydrazide compound and preparation method and application thereof | 南京农业大学 | 2026-05-15 | — | — | CN | disclosed |
| US-12612424-B2 | HPK1 inhibitors and uses thereof | REGOR PHARMACEUTICALS, INC. (US) | 2026-04-28 | — | — | US | disclosed |
| US-12570675-B2 | Boronic acid compounds | LG CHEM, LTD. (KR) | 2026-03-10 | — | — | US | disclosed |
| CN-1222153-A | Piperidine acetic acid derivatives and their use in the treatment of thrombotic disorders | GLAXO GROUP LTD (GB) | 1999-07-07 | — | — | CN | disclosed |
| EP-0912555-A1 | PIPERIDINE ACETIC ACID DERIVATIVES AND THEIR USE IN THE TREATMENT OF THROMBOTIC DISORDERS | GLAXO GROUP LIMITED (GB) | 1999-05-06 | — | — | EP | disclosed |
| WO-1997049699-A1 | PIPERIDINE ACETIC ACID DERIVATIVES AND THEIR USE IN THE TREATMENT OF THROMBOTIC DISORDERS | GLAXO GROUP LIMITED (GB) | 1997-12-31 | — | — | WO | disclosed |
| WO-1997049698-A1 | PIPERIDINE ACETIC ACID DERIVATIVES AND THEIR USE IN THE TREATMENT OF THROMBOTIC DISORDERS | GLAXO GROUP LIMITED (GB) | 1997-12-31 | — | — | WO | disclosed |
| WO-1997023480-A1 | NOVEL INTEGRIN RECEPTOR ANTAGONISTS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1997-07-03 | — | — | WO | disclosed |
| US-5331006-A | Cholecystokinin, antisecretory agents | WARNER-LAMBERT COMPANY (US) | 1994-07-19 | — | — | US | disclosed |
| US-5137895-A | Antiemetic, anxiolytic, gastric emptying and serotonin modulating activity | A. H. ROBINS COMPANY, INCORPORATED (US) | 1992-08-11 | — | — | US | disclosed |
| WO-1992004025-A1 | AMINO ACID ANALOGS AS CCK ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1992-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12612424-B2 | HPK1 inhibitors and uses thereof | NEK11, NEK1, CSNK1A1 | KDM4E 2717/4885STAT3 3254/4885HIF1A 1709/4885 |
| US-12570675-B2 | Boronic acid compounds | PSMB6, PSMB3, PSMB2 | KDM4E 3458/4885STAT3 4643/4885HIF1A 2157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.